Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gennex Laboratories has submitted to BSE, Ahmedabad Stock Exchange, and Calcutta Stock Exchange the newspaper clippings of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26). The results were approved by the Board on August 14, 2025 and published on August 15, 2025 in Business Standard (English) and Saksham (Telugu local). The company reported a loss before tax of approximately Rs. 297.67 lakhs and a loss after tax of about Rs. 416.40 lakhs on a standalone basis, with a negative EPS of Rs. (0.295). Total income for the quarter stood at around Rs. 444.95 lakhs.
The filing is a routine regulatory compliance submission of already-published results. The underlying Q1 numbers show the company remained loss-making with a widened net loss versus the previous year-ago quarter, which is a negative signal for shareholders and may weigh on near-term sentiment.